What is the appropriate treatment regimen for Evan's syndrome, including first‑line therapy, dosing, and second‑line options?

Treatment of Evans Syndrome

Treat Evans syndrome with first-line corticosteroids (prednisone) combined with intravenous immunoglobulin (IVIg 1 g/kg), followed by rituximab as second-line therapy for refractory or relapsing disease. 1

First-Line Therapy

The initial treatment approach differs from isolated immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA) because Evans syndrome carries higher relapse rates, more severe complications, and requires more aggressive management 1, 2.

Start with:

• Prednisone (typically 1 mg/kg/day) as the cornerstone therapy
• Add IVIg (1 g/kg as single dose, repeatable if necessary) when rapid platelet increase is needed or in severe presentations 3, 1

Important dosing distinction: The duration and tapering schedule should differ between the thrombocytopenic and hemolytic components. Longer corticosteroid courses are preferred over short high-dose pulses 3. The 2024 consensus specifically recommends different treatment durations for ITP versus AIHA components 1.

Critical caveat: Anti-D immunoglobulin should be avoided in patients with decreased hemoglobin from bleeding or evidence of autoimmune hemolysis 3, making it generally inappropriate for Evans syndrome where hemolysis is a defining feature.

Second-Line Therapy

Rituximab is the strongly recommended second-line agent for Evans syndrome, particularly in specific scenarios 1:

• Cold-type AIHA: Rituximab moves to first-line treatment
• Warm-type AIHA with ITP: Second-line after corticosteroid failure
• Patients with antiphospholipid antibodies or previous thrombotic events
• Associated lymphoproliferative diseases

Rituximab achieves response rates of approximately 62.5% in refractory cases, though long-term sustained responses at one year may be only 30-35% 3, 4. Despite this limitation, it has become the most widely used second-line treatment because it safely achieves high initial response rates and can postpone or avoid splenectomy 4, 5.

Contraindications to rituximab:

• Immunodeficiency disorders
• Severe active infections
• Autoimmune lymphoproliferative syndrome (ALPS) - where mycophenolate mofetil or sirolimus are preferred 1, 5

Third-Line and Beyond

When rituximab fails or is contraindicated:

For the thrombocytopenic component:

• Thrombopoietin receptor agonists (TPO-RAs) are recommended for chronic ITP, especially with history of grade 4 infections 3, 1
• Fostamatinib is recommended as third-line or suggested as second-line for patients with previous thrombotic events 1

For refractory disease:

• Immunosuppressive agents (mycophenolate mofetil, cyclosporine) have been moved to third-line or further-line treatment in the 2024 consensus 1, 6
• Splenectomy should be delayed at least 12 months unless severe disease is unresponsive to other measures 3. It is discouraged in patients with immunodeficiency or severe infections 1. Long-term remissions are less frequent in Evans syndrome compared to isolated ITP 6

For lymphoproliferative-associated Evans syndrome:

• Rituximab plus bendamustine combination is specifically recommended 1

Adjunctive Therapies

The 2024 consensus provides specific recommendations for supportive care 1:

• Recombinant erythropoietin for AIHA with inadequate reticulocyte response
• Sutimlimab (complement inhibitor) for relapsed cold AIHA
• Appropriate thrombotic prophylaxis given the increased thrombotic risk
• Antibiotic prophylaxis considerations

Critical Pitfalls to Avoid

1. Do not treat Evans syndrome like isolated ITP or AIHA - it requires more aggressive initial therapy and has different relapse patterns 1, 2

2. Avoid splenectomy as early intervention - unlike isolated ITP where splenectomy is recommended after corticosteroid failure 3, in Evans syndrome it should be reserved for truly refractory cases after at least 12 months and multiple medical therapies 1

3. Screen for underlying conditions - 25% of Evans syndrome cases have associated lymphoproliferative disorders, autoimmune diseases, or primary immunodeficiencies that require specific management 1, 2

4. Monitor for infectious and thrombotic complications - these are more common in Evans syndrome than isolated cytopenias and influence treatment choices 1, 2

The evidence base for Evans syndrome management has evolved significantly, with the 2024 consensus 1 representing the most comprehensive and recent guidance, superseding the approach of simply combining ITP and AIHA treatment guidelines [3-3]. The key paradigm shift is recognizing Evans syndrome as a distinct entity requiring more aggressive immunosuppression and careful attention to complications.